Givosiran ALA PKPD Model
Indication: Acute Hepatic Porphyria
PK/PD model of urinary ALA reduction with givosiran in acute hepatic porphyria. Alnylam siRNA therapeutic targeting ALAS1.
Drug Overview
Clinical Context
- Molecular Target
- ALAS1
- Drug Class
- siRNA
- Therapeutic Area
- Rare Disease
- Indication
- Acute Hepatic Porphyria
- Route of Administration
- SC
Model Information
- Model Type
- PK-turnover (indirect response)
- Category
- PK/PD
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
Pharmacokinetic Parameters
PK Parameters
| Parameter | Value |
|---|---|
| ka | 0.308 h⁻¹ |
| CL F | 38.8 L/h |
| Vc F | 26.3 L |
PD Parameters
| Parameter | Value |
|---|---|
| Emax | 0.95 |
| IC50 ALA | ~0.5 ng/mL |
Additional Parameters
| Parameter | Value |
|---|---|
| dose | 2.5 mg/kg SC monthly |
Parameters sourced from published population pharmacokinetic models. Values represent typical population estimates; individual patient parameters may vary.
About This Simulator
This interactive pharmacokinetic simulator for Givosiran ALA allows you to explore concentration-time profiles under different dosing scenarios. The underlying PK/PD model characterizes the pharmacokinetics of this sirna following sc administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration). The pharmacodynamic component links drug exposure to therapeutic or safety endpoints.
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the Givosiran ALA PK simulator?
This is a free, interactive pharmacokinetic simulator for Givosiran ALA used in Acute Hepatic Porphyria. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does Givosiran ALA belong to?
Givosiran ALA is classified as a siRNA that targets ALAS1. It is used in the Rare Disease therapeutic area.
What route of administration does this model simulate?
This simulator models SC administration of Givosiran ALA. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a PK/PD model. PK/PD models link drug concentrations to pharmacological effects, allowing exploration of exposure-response relationships.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
What is the clearance of Givosiran ALA?
The clearance (CL) of Givosiran ALA is approximately 38.8 L/h. Clearance represents the volume of plasma from which drug is completely removed per unit time and is a key determinant of drug exposure and steady-state concentrations.
Related Simulators
Ready to Simulate?
Launch the Givosiran ALA simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community